Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Assets (2017 - 2025)

Puma Biotechnology's Other Non-Current Assets history spans 9 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2146.22% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, up 2146.22%, while the annual FY2025 figure was $2.7 million, 2146.22% up from the prior year.
  • Other Non-Current Assets reached $2.7 million in Q4 2025 per PBYI's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $12.2 million in Q1 2021 to a low of $119000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $3.0 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: tumbled 96.91% in 2022, then surged 2146.22% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.3 million in 2021, then fell by 21.47% to $2.6 million in 2022, then increased by 5.15% to $2.7 million in 2023, then crashed by 95.65% to $119000.0 in 2024, then soared by 2146.22% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Other Non-Current Assets are $2.7 million (Q4 2025), $1.8 million (Q3 2025), and $2.1 million (Q2 2025).